A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)

Change in percentage involved Body Surface Area (BSA) from start of deucravacitinib treatment

Time frame: Baseline and at months 4, 12, 18 (optional), and 24

Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Itch

Time frame: Baseline and months 1, 4, 12, 18 (optional) and 24

Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Skin pain

Time frame: Baseline and months 1, 4, 12, 18 (optional) and 24

Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS)] - Fatigue

Time frame: Baseline and months 1, 4, 12, 18 (optional) and 24

Physician's Global Assessment (PGA) score change from start of deucravacitinib treatment to follow-up

Time frame: Baseline and at months 4, 12, 18 (optional), and 24

Dermatology Life Quality Index (DLQI) score of ≤5

Time frame: Baseline and at months 1, 4, 12 18 (optional) and 24